Our findings further suggest that genomic instability due to PI3K depletion should be considered an important side effect in anticancer therapies based on PI3K inhibitors, along with hyperinsulinemia and hyperglycemia (Nunnery & Mayer, 2019). This evidence concerns the gene PIK3CD and Hyperglycemia.